ABSTRACT
Diagnosis and treatment of Behçet's disease (BD) have continued to undergo new changes in recent years. We organized a Compilation Committee for Guidelines on Diagnosis and Treatment of Ocular Behçet's Disease with five ophthalmology research facilities in Japan (Hokkaido University, Health Sciences University of Hokkaido, University of Tokyo, Tokyo Medical University, and Yokohama City University), and accomplished the Major review of Current aspects of Ocular Behçet's Disease in Japan. The review consist of four chapters: introduction, ocular lesions, diagnosis, and treatment. We are very pleased if the guidelines are found to be effective and useful in improving the quality of life (QOL) and quality of vision (QOV) of BD patients in the world.
Subject(s)
Behcet Syndrome , Disease Management , Uveitis, Anterior/epidemiology , Behcet Syndrome/diagnosis , Behcet Syndrome/epidemiology , Behcet Syndrome/therapy , Humans , Japan/epidemiology , Morbidity/trendsABSTRACT
PURPOSE: To characterize retinal macroaneurysm, which although rare, has been reported as a specific complication of ocular sarcoidosis. METHODS: Ninety-seven sarcoidosis patients with intraocular inflammation diagnosed at the Uveitis Clinic of Tokyo Medical University Hospital between 1997 and 2006 were analyzed retrospectively. RESULTS: Retinal macroaneurysm was found in nine eyes of seven patients (7.2%). The mean patient age at onset was 61 years, similar to the reported onset age in patients with macroaneurysm not associated with ocular sarcoidosis. Most aneurysms developed in the chronic phase, and not in the early phase, of ocular sarcoidosis. Two patients (29%) were affected bilaterally. Five of nine eyes (56%) had multiple lesions. Unlike retinal macroaneurysm not associated with sarcoidosis, which is usually solitary and unilateral, rates of bilateral and multiple lesions were high. CONCLUSIONS: The clinical features of retinal aneurysm associated with ocular sarcoidosis are considerably different from those of unilateral macroaneurysm not associated with sarcoidosis.
Subject(s)
Aneurysm/etiology , Eye Diseases/complications , Retinal Diseases/etiology , Sarcoidosis/complications , Adult , Aged , Aged, 80 and over , Aneurysm/diagnosis , Female , Fluorescein Angiography , Humans , Male , Middle Aged , Retinal Diseases/diagnosis , Retrospective StudiesABSTRACT
Mice deficient in superoxide dismutase 1 (Sod1(-/-) mice) develop many features seen in patients with age-related macular degeneration (AMD) including choroidal neovascularization (NV). We sought to determine if the absence of SOD1 contributes to the pro-angiogenic environment in the subretinal space or whether it is completely secondary to other changes in Bruch's membrane and the retinal pigmented epithelium (RPE) that precede the development of choroidal NV. In an ischemic retinopathy model or a transgenic model in which the rhodopsin promoter drives expression of vascular endothelial growth factor (VEGF) in photoreceptor there was significantly more NV in Sod1(-/-) compared to Sod1(+/+) mice. The compromised antioxidant defense system in Sod1(-/-) mice contributes to the pro-angiogenic environment, because treatment of Sod1(-/-) mice with a mixture of antioxidants caused a significant reduction in ischemia-induced retinal NV. Wild-type mice treated with the same antioxidants also showed reduced ischemia-induced retinal NV, reduced VEGF-induced subretinal NV, and reduced choroidal NV at Bruch's membrane rupture sites. These data suggest that reactive oxygen species contribute to several types of ocular NV. This could explain why in the Age-Related Eye Disease Trial, antioxidant treatment reduced conversion from non-neovascular to neovascular AMD and severe vision loss, and suggest that potent antioxidants should be considered for other diseases complicated by ocular NV. J. Cell. Physiol. 219: 544-552, 2009. (c) 2009 Wiley-Liss, Inc.
Subject(s)
Choroidal Neovascularization/etiology , Choroidal Neovascularization/metabolism , Oxidative Stress , Retinal Neovascularization/etiology , Retinal Neovascularization/metabolism , Animals , Antioxidants/pharmacology , Choroidal Neovascularization/drug therapy , Disease Models, Animal , Humans , Ischemia/complications , Ischemia/drug therapy , Macular Degeneration/drug therapy , Macular Degeneration/etiology , Macular Degeneration/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Reactive Oxygen Species/metabolism , Retinal Neovascularization/drug therapy , Retinal Vessels , Superoxide Dismutase/deficiency , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism , Superoxide Dismutase-1 , Vascular Endothelial Growth Factor A/geneticsABSTRACT
Equine infectious anemia virus (EIAV) is a nonprimate lentivirus that does not cause human disease. Subretinal injection into mice of a recombinant EIAV lentiviral vector in which lacZ is driven by a CMV promoter (EIAV CMV LacZ) resulted in rapid and strong expression of LacZ in retinal pigmented epithelial (RPE) cells and some other cells including ganglion cells, resulting in the presence of 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside within the optic nerve. Substitution of the RPE-specific promoter from the vitelliform macular dystrophy (VMD2) gene for the CMV promoter resulted in prolonged (at least 1 year) expression of LacZ that was restricted to RPE cells, albeit reduced 6- to 10-fold compared with the CMV promoter. Similarly, the amount of FLAG-tagged endostatin detected in eyes injected with the EIAV VMD2 Endo(FLAG) vector was similar to that seen in eyes injected with a vector that expressed both endostatin and angiostatin [EIAV VMD2 Endo(FLAG)/Angio]; expression was approximately 6-fold lower than with identical vectors in which the CMV promoter drove expression. Compared with murine eyes treated with a control EIAV vector, subretinal injection of EIAV vectors expressing murine endostatin alone or in combination with angiostatin driven by either the CMV or VMD2 promoter caused significant suppression of choroidal neovascularization (NV) at laser-induced rupture sites in Bruch's membrane. These data support proceeding toward clinical studies with EIAV-based gene therapy for choroidal NV, using the VMD2 promoter to selectively drive expression of a combination of endostatin and angiostatin in RPE cells.
Subject(s)
Angiostatins/genetics , Choroidal Neovascularization/therapy , Endostatins/genetics , Genetic Vectors/administration & dosage , Infectious Anemia Virus, Equine/genetics , Retinal Pigment Epithelium/metabolism , Angiostatins/metabolism , Animals , Bestrophins , Disease Models, Animal , Endostatins/metabolism , Eye Proteins/genetics , Eye Proteins/metabolism , Female , Gene Expression Regulation , Genetic Therapy/methods , Genetic Vectors/genetics , Humans , Infectious Anemia Virus, Equine/physiology , Ion Channels , Mice , Mice, Inbred C57BL , Promoter Regions, Genetic , Retinal Pigment Epithelium/virology , Treatment OutcomeABSTRACT
PURPOSE: Nicotinic acetylcholine receptors (nAChR) are best known for their role in neurotransmission, but they have recently been demonstrated on vascular endothelial cells. Acetylcholine is their endogenous ligand, but they are also stimulated by nicotine. By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovascularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV). METHODS: The effect of the nonselective nAChR antagonist mecamylamine was tested on human retinal and choroidal endothelial cells in vitro and in a murine model of CNV. RESULTS: Several nAChR isoforms were identified in retinal and choroidal microvascular endothelial cells, and the ability of these cells to form tubules when grown in growth factor-reduced basement membrane matrix and supplemented with VEGF was suppressed by the nAChR antagonist mecamylamine. Supplementation of the drinking water of mice with nicotine increased the size of CNV lesions at Bruch membrane rupture sites, an effect that was blocked by subcutaneous administration of mecamylamine (50 mg/kg/d) by an osmotic pump. In the absence of nicotine, CNV formation was suppressed by the infusion of 50 mg/kg/d mecamylamine or by topical application 0.1 or 1% mecamylamine to the cornea. CONCLUSIONS: These data suggest that endogenous activation of nAChR promotes CNV and that activation of nAChR by nicotine may contribute to the increased incidence of CNV seen in smokers with age-related macular degeneration (AMD). Topically administered mecamylamine could provide an appealing new treatment approach for CNV.
Subject(s)
Choroidal Neovascularization/prevention & control , Disease Models, Animal , Endothelium, Vascular/drug effects , Mecamylamine/pharmacology , Nicotine/pharmacology , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/metabolism , Animals , Cells, Cultured , Choroid/blood supply , Choroidal Neovascularization/etiology , Choroidal Neovascularization/metabolism , Endothelium, Vascular/metabolism , Female , Humans , Immunoblotting , Mecamylamine/administration & dosage , Mice , Mice, Inbred C57BL , Protein Isoforms/metabolism , RNA, Messenger/metabolism , Receptors, Nicotinic/genetics , Retinal Vessels/cytologyABSTRACT
Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeting the VEGFr pathway may be effective for the treatment of AMD. Recent studies using Src/YES knockout mice suggest that along with VEGF, Src and YES play a crucial role in vascular leak and might be useful in treating edema associated with AMD. Therefore, we have developed several potent benzotriazine inhibitors designed to target VEGFr2, Src, and YES. One of the most potent compounds is 4-chloro-3-{5-methyl-3-[4-(2-pyrrolidin-1-yl-ethoxy)phenylamino]benzo[1,2,4]triazin-7-yl}phenol ( 5), a dual inhibitor of both VEGFr2 and the Src family (Src and YES) kinases. Several ester analogues of 5 were prepared as prodrugs to improve the concentration of 5 at the back of the eye after topical administration. The thermal stability of these esters was studied, and it was found that benzoyl and substituted benzoyl esters of 5 showed good thermal stability. The hydrolysis rates of these prodrugs were studied to analyze their ability to undergo conversion to 5 in vivo so that appropriate concentrations of 5 are available in the back-of-the-eye tissues. From these studies, we identified 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate ( 12), a topically administered prodrug delivered as an eye drop that is readily converted to the active compound 5 in the eye. This topically delivered compound exhibited excellent ocular pharmacokinetics and poor systemic circulation and showed good efficacy in the laser induced choroidal neovascularization model. On the basis of its superior profile, compound 12 was advanced. It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD.
Subject(s)
Macular Degeneration/drug therapy , Ophthalmic Solutions/therapeutic use , Phenols/therapeutic use , Prodrugs/therapeutic use , Triazines/therapeutic use , Administration, Topical , Animals , Choroidal Neovascularization/drug therapy , Clinical Trials as Topic , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Design , Eye/drug effects , Eye/radiation effects , Lasers , Mice , Mice, Knockout , Models, Molecular , Molecular Structure , Ophthalmic Solutions/chemistry , Ophthalmic Solutions/pharmacokinetics , Phenols/chemistry , Phenols/pharmacokinetics , Prodrugs/chemistry , Prodrugs/pharmacokinetics , Structure-Activity Relationship , Triazines/chemistry , Triazines/pharmacokinetics , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , src-Family Kinases/antagonists & inhibitorsABSTRACT
Age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions are complicated by neovascularization and macular edema. Multi-targeted kinase inhibitors that inhibit select growth factor receptor tyrosine kinases and/or components of their down-stream signaling cascades (such as Src kinases) are rationale treatment strategies for these disease processes. We describe the discovery and characterization of two such agents. TG100572, which inhibits Src kinases and selected receptor tyrosine kinases, induced apoptosis of proliferating endothelial cells in vitro. Systemic delivery of TG100572 in a murine model of laser-induced choroidal neovascularization (CNV) caused significant suppression of CNV, but with an associated weight loss suggestive of systemic toxicity. To minimize systemic exposure, topical delivery of TG100572 to the cornea was explored, and while substantial levels of TG100572 were achieved in the retina and choroid, superior exposure levels were achieved using TG100801, an inactive prodrug that generates TG100572 by de-esterification. Neither TG100801 nor TG100572 were detectable in plasma following topical delivery of TG100801, and adverse safety signals (such as weight loss) were not observed even with prolonged dosing schedules. Topical TG100801 significantly suppressed laser-induced CNV in mice, and reduced fluorescein leakage from the vasculature and retinal thickening measured by optical coherence tomography in a rat model of retinal vein occlusion. These data suggest that TG100801 may provide a new topically applied treatment approach for ocular neovascularization and retinal edema.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Choroidal Neovascularization/drug therapy , Papilledema/drug therapy , Phenols/therapeutic use , Prodrugs/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Triazines/therapeutic use , src-Family Kinases/antagonists & inhibitors , Administration, Topical , Angiogenesis Inhibitors/adverse effects , Angiogenesis Inhibitors/metabolism , Animals , Cell Line , Choroidal Neovascularization/pathology , Female , Humans , Mice , Mice, Inbred C57BL , Papilledema/pathology , Prodrugs/adverse effects , Prodrugs/metabolism , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/metabolism , Rabbits , Rats , Rats, Long-Evans , Receptor Protein-Tyrosine Kinases/metabolism , Retina/cytology , Retina/metabolism , Retina/pathology , src-Family Kinases/metabolismABSTRACT
Zinc finger protein transcription factors (ZFP TFs) have been shown to positively or negatively regulate the expression of endogenous genes involved in a number of different disease processes. In this study we investigated whether gene transfer of an engineered ZFP TF designed to up-regulate expression of the chromosomal pigment epithelium-derived factor (Pedf) gene could suppress experimentally induced choroidal neovascularization (CNV). Transient transfection with engineered ZFP TFs significantly increased both Pedf messenger RNA (mRNA) and secreted PEDF protein levels in cell culture. Six weeks after intravitreous or subretinal injection of an adeno-associated viral (AAV) vector expressing the PEDF-activating ZFP TF in mice, we observed increased retinal Pedf mRNA, and a significant reduction in the size of CNV at Bruch's membrane rupture sites, assessed in vivo by fluorescein angiography or by postmortem measurements on choroidal flat mounts. Importantly, the anti-angiogenic activity persisted at 3 months after intravitreous injection. These data suggest that ZFP TF-driven enhancement of the endogenous anti-angiogenic defense system may provide a new approach for prophylaxis and treatment of neovascular diseases of the eye.
Subject(s)
Neovascularization, Physiologic , Transcription Factors/metabolism , Zinc Fingers , Adenoviridae/genetics , Animals , Eye Proteins/genetics , Eye Proteins/metabolism , Gene Expression , Genetic Vectors/genetics , Humans , Mice , Neovascularization, Physiologic/genetics , Nerve Growth Factors/genetics , Nerve Growth Factors/metabolism , RNA, Messenger/genetics , Retina/metabolism , Serpins/genetics , Serpins/metabolism , Time Factors , Transcription Factors/genetics , TransfectionABSTRACT
PURPOSE: Self-complementary AAV (scAAV) vectors have been developed to circumvent rate-limiting second-strand synthesis in single-stranded AAV vector genomes and to facilitate robust transgene expression at a minimal dose. In this study, the authors investigated the effects of intraocular injections of type 2 scAAV.GFP in mice. METHODS: Dose-response experiments were performed to compare conventional single-strand AAV type 2 (ssAAV2) vectors with scAAV2 vectors encoding an identical expression cassette. RESULTS: Subretinal injection of 5 x 10(8) viral particles (vp) of scAAV.CMV-GFP resulted in green fluorescent protein (GFP) expression in almost all retinal pigment epithelial (RPE) cells within the area of the small detachment caused by the injection by 3 days and strong, diffuse expression by 7 days. Expression was strong in all retinal cell layers by days 14 and 28. In contrast, 3 days after subretinal injection of 5 x 10(8) vp of ssAAV.CMV-GFP, GFP expression was detectable in few RPE cells. Moreover, the ssAAV vector required 14 days for the attainment of expression levels comparable to those observed using scAAV at day 3. Expression in photoreceptors was not detectable until day 28. Dose-response experiments confirmed that onset of GFP expression was more rapid and robust after subretinal injection of scAAV.CMV-GFP than of ssAAV.CMV-GFP, resulting in pronounced expression in photoreceptors and other retinal neurons. Similar results were obtained for intravitreous injections. CONCLUSIONS: These data suggest that scAAV vectors may be advantageous for ocular gene therapy, particularly in retinal diseases that require rapid and robust transgene expression in photoreceptor cells.
Subject(s)
Dependovirus/genetics , Gene Expression Regulation/physiology , Gene Transfer Techniques , Genetic Vectors , Green Fluorescent Proteins/genetics , Pigment Epithelium of Eye/metabolism , Animals , Female , Genetic Therapy , Mice , Mice, Inbred BALB C , Microscopy, Fluorescence , Plasmids , TransgenesABSTRACT
Hypoxia causes increased expression of several proteins that have the potential to promote neovascularization. Vascular endothelial growth factor (VEGF) is up-regulated by hypoxia in the retina and plays a central role in the development of several types of ocular neovascularization, but the effects of other hypoxia-regulated proteins are less clear. Stromal-derived factor-1 (SDF-1) and its receptor, CXCR4, have hypoxia response elements in the promoter regions of their genes and are increased in hypoxic liver and heart. In this study, we found that SDF-1 and CXCR4 are increased in hypoxic retina, with SDF-1 localized in glial cells primarily near the surface of the retina and CXCR4 localized in bone marrow-derived cells. Glial cells also expressed CXCR4, which suggested the possibility of autocrine stimulation, but influx of bone marrow-derived cells is the major source of increased levels of CXCR4. High levels of VEGF in the retina in the absence of hypoxia also increased levels of Cxcr4 and Sdf1 mRNA. CXCR4 antagonists reduced influx of bone marrow-derived cells into ischemic retina and strongly suppressed retinal neovascularization, VEGF-induced subretinal neovascularization, and choroidal neovascularization. These data suggest that SDF-1 and CXCR4 contribute to the involvement of bone marrow-derived cells and collaborate with VEGF in the development of several types of ocular neovascularization. They provide new targets for therapeutic intervention that may help to bolster and supplement effects obtained with VEGF antagonists.
Subject(s)
Chemokine CXCL12/metabolism , Corneal Neovascularization , Hypoxia , Receptors, CXCR4/metabolism , Retina/anatomy & histology , Retina/physiology , Retinal Neovascularization , Animals , Antigens, Differentiation/metabolism , Bone Marrow Cells , Chemokine CXCL12/genetics , Humans , Ischemia/metabolism , Leukocyte Common Antigens/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Oligopeptides/metabolism , Platelet Endothelial Cell Adhesion Molecule-1/genetics , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Pyridines/metabolism , Receptors, CXCR4/antagonists & inhibitors , Receptors, CXCR4/genetics , Retina/pathology , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolismABSTRACT
PURPOSE: To compare the conjunctival flora of human immunodeficiency virus (HIV)-positive and HIV-negative patients. Also, to assess the prophylactic effect of oral clarithromycin against Mycobacterium avium complex on the conjunctival flora of HIV-positive patients. METHODS: Ninety-four eyes of 47 HIV-positive patients and 122 eyes of 61 control patients were examined. All participants had a detailed anterior segment examination, including conjunctival cultures and laboratory blood tests. Culture results for different organisms were evaluated by chi-square analysis between the groups. The effect of systemic antibiotic treatment on the conjunctival flora of patients with HIV infection was evaluated by chi-square analysis. RESULTS: Bacterial organisms in the conjunctival sac were detected in four out of 28 (14.3%) eyes of HIV-positive patients treated with systemic clarithromycin and in 32 out of 66 (48.5%) eyes of HIV-positive patients without systemic clarithromycin treatment (p < 0.01). The CD4-positive T-cell counts in these groups were 158/microl and 416/microl, respectively (p < 0.01). Bacterial organisms were also detected in 46 of 122 (37.7%) control eyes. No difference was observed in the types and proportions of organisms isolated from the conjunctiva between HIV-positive patients without systemic clarithromycin treatment and controls. CONCLUSION: There was no difference between the conjunctival flora of HIV-negative and HIV-positive patients. Systemic clarithromycin treatment decreased the conjunctival flora of HIV patients, including those who had a CD4 count that was less than 50/microl.
Subject(s)
Conjunctiva/microbiology , HIV Infections/microbiology , Adult , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Bacteriological Techniques , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , Clarithromycin/therapeutic use , Colony Count, Microbial , Conjunctiva/drug effects , Drug Combinations , Female , HIV Infections/drug therapy , HIV Infections/immunology , Humans , Male , Sulfamethoxazole/analogs & derivatives , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic useABSTRACT
PURPOSE: To characterize the clinical features of ocular toxocariasis and to describe the unique aspects of the disease in Japan. METHODS: Thirty-six cases diagnosed as ocular toxocariasis at the uveitis clinic of Tokyo Medical University Hospital were analyzed retrospectively. RESULTS: Thirty-six cases comprised 34 adults (average age: 39 +/- 10 years) and two nine-year-old boys. All cases were classified into two clinical types: posterior pole type (13 cases) and peripheral type (23 cases). Visual acuity was maintained over 20/20 in 50% and less than 20/200 in 14% of the cases. The peripheral type had worse outcomes than the posterior pole type in all of the endpoints examined: final visual outcome, frequency of ocular complications, and effectiveness of vitreous surgery. Antibody titers in intraocular fluids led to a diagnosis of ocular toxocariasis in eight seronegative cases of 33 cases examined for antibodies in both serum and intraocular fluid samples. CONCLUSIONS: The peripheral type had a worse prognosis than the posterior pole type. However, in general, ocular toxocariasis resulted in fair visual outcomes. The antibody titer in intraocular fluid was helpful in the diagnosis.
Subject(s)
Eye Infections, Parasitic/diagnosis , Toxocariasis/diagnosis , Uveal Diseases/diagnosis , Adult , Animals , Antibodies, Helminth/blood , Antigens, Helminth/immunology , Child , Diethylcarbamazine/therapeutic use , Drug Therapy, Combination , Enzyme-Linked Immunosorbent Assay , Eye Infections, Parasitic/drug therapy , Eye Infections, Parasitic/epidemiology , Female , Humans , Japan/epidemiology , Male , Middle Aged , Prednisolone/therapeutic use , Prevalence , Retrospective Studies , Toxocara canis/immunology , Toxocariasis/drug therapy , Toxocariasis/epidemiology , Uveal Diseases/drug therapy , Uveal Diseases/epidemiology , Vitreous Body/immunology , Vitreous Body/parasitologyABSTRACT
We produced a new monoclonal antibody (mAb) to the excretory-secretory (ES) antigens of Toxocara canis larvae. The mAb (IgG1) reacts specifically with the 120 kDa protein of many ES molecules and does not have any cross-reactivity with adult T. canis antigens. Sandwich ELISA to detect the ES antigens was performed using the mAb and rabbit polyclonal antiserum. The lower limit for the detection of ES antigen was 4 ng/ml; assay was proportional within a concentration range of 4 ng/ml to 1 microg/ml of ES antigen. This assay system may prove valuable when seeking to quantify parasite burden early in infection and when determining the efficacy of anthelmintic treatment.